CEA has been increasingly used to inform public and private organizations’ reimbursement decisions, benefit designs, and price negotiations worldwide.

Insurers’ decisions about which services to cover are often based on economic models that are seemingly objective but neglect factors affecting people who are economically disadvantaged.

A wire, plaster, and wood sculpture of a DNA double helix with one mismatched base pair considers how we might justly weigh overall health equity against extremely costly interventions for uncommon genetic illnesses.

Heightened caution, improved physician and patient communication, and equitable access are key priorities.

If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.

Elina E. Pliakos and Dr Ankur Pandya join Ethics Talk to discuss how economic decision modeling and value analyses can help reduce waste in health care spending and improve patient care.

Drs David D. Kim and Anirban Basu join Ethics Talk to discuss their article: "How Does Cost-Effectiveness Analysis Inform Health Care Decisions?"

Beatrice L. Brown joins Ethics Talk to discuss her article, coauthored with Dr Aaron S Kesselheim: "How Should Clinicians and Organizations Assess Risks and Benefits of First-in-Human Implantation of Investigational Devices?"

Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"

Standards for posttransplant graft/survival rates do not reward transplant centers for performing riskier transplants to increase population benefit.